SCHEMBL109364

SCHEMBL109364

COC(=O)c1ccc(Br)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.65
KDM4E B2RXH2 5/20 0.60
ALDH1A1 P00352 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 4/20 0.49
TP53 P04637 1/20 0.49
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CYP1A2 P05177 2/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
LCK P06239 1/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30978460 1.00 MAPK1 (0.65) MAPK1KDM4EALDH1A1L3MBTL1MAPT
SCHEMBL6201156 0.93 MAPK1 (0.57) MAPK1KDM4EALDH1A1L3MBTL1MAPT
SCHEMBL15932170 0.81 KDM4E (0.56) MAPK1KDM4EALDH1A1L3MBTL1MAPT
SCHEMBL28049209 0.81 KDM4E (0.60) MAPK1KDM4EALDH1A1L3MBTL1NPC1
SCHEMBL28020808 0.81 KDM4E (0.60) MAPK1KDM4EALDH1A1L3MBTL1NPC1
SCHEMBL28934033 0.80 ALDH1A1 (0.55) MAPK1KDM4EALDH1A1MAPTRAB9A
SCHEMBL645688 0.80 KDM4E (0.55) MAPK1KDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL1808295 0.80 ALDH1A1 (0.55) MAPK1KDM4EALDH1A1MAPTLMNA
SCHEMBL31407736 0.80 KDM4E (0.55) MAPK1KDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL30785982 0.79 KDM4E (0.53) MAPK1KDM4EALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119192071-A Preparation method of 5-bromopyridine-2-carboxylic acid methyl ester 济南泺合医药技术有限公司 2024-12-27 CN claimed
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 US disclosed
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-05-26 US disclosed
CN-116348115-B Combination of antibody-drug conjugate and PARP1 selective inhibitor ASTRAZENECA UK LTD. (GB) 2026-05-26 CN disclosed
EP-4743453-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 EP disclosed
CN-122059929-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-19 CN disclosed
CN-122036686-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN disclosed
CN-122036687-A Quinoxaline derivatives as anticancer agents 阿斯利康(瑞典)有限公司 2026-05-15 CN disclosed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 US disclosed
US-20040171614-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION 2004-09-02 US disclosed
US-20040171614-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION 2004-09-02 US disclosed
EP-1411928-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-04-28 EP disclosed
US-20040048848-A1 Novel gamma secretase inhibitors SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. 2004-03-11 US disclosed
WO-2004006923-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 WO disclosed
WO-2004006922-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 WO disclosed
WO-2004000814-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-12-31 WO disclosed
US-20030236251-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-12-25 US disclosed
WO-2003066592-A1 GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2003-08-14 WO disclosed
WO-2003007945-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171614-A1 Novel gamma secretase inhibitors BACE1, BACE2, APP MAPK1 3535/4885KDM4E 2433/4885ALDH1A1 4012/4885
US-20040048848-A1 Novel gamma secretase inhibitors BACE1, BACE2, PSEN1 MAPK1 3600/4885KDM4E 1995/4885ALDH1A1 1953/4885
US-20030236251-A1 Viral polymerase inhibitors POLR2H, CTDSP1, POLR2E MAPK1 3048/4885KDM4E 2771/4885ALDH1A1 3269/4885
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators GABRA6, GABRA1, GABRB1 MAPK1 2422/4885KDM4E 3564/4885ALDH1A1 632/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR MAPK1 4489/4885KDM4E 3829/4885ALDH1A1 3360/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 MAPK1 1400/4885KDM4E 627/4885ALDH1A1 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.